| Literature DB >> 16912957 |
David W Haas1, John A Bartlett, Janet W Andersen, Ian Sanne, Grant R Wilkinson, John Hinkle, Franck Rousseau, Christiana D Ingram, Audrey Shaw, Michael M Lederman, Richard B Kim.
Abstract
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).Entities:
Mesh：
Substances：
Year: 2006 PMID： 16912957 DOI： 10.1086/507097
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079